The invention provides novel non-peptidic NPY Y2 receptor inhibitors
useful in treating or preventing: anxiolytic disorders or depression;
injured mammalian nerve tissue; conditions responsive to treatment
through administration of a neurotrophic factor; neurological disorders;
bone loss; substance related disorders; obesity; or an obesity-related
disorder. Compounds of the invention are also useful in modulating
endocrine functions, particularly endocrine functions controlled by the
pituitary and hypothalamic glands, and are therefore useful in the
treatment or prevention of inovulation and infertility.